Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PRRX1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRRX1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRRX1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PRRX1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRRX1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00310997 | Endometrium | AEH | regeneration | 41/2100 | 198/18723 | 7.29e-05 | 1.11e-03 | 41 |
GO:00109758 | Endometrium | AEH | regulation of neuron projection development | 75/2100 | 445/18723 | 2.01e-04 | 2.54e-03 | 75 |
GO:00351073 | Endometrium | AEH | appendage morphogenesis | 29/2100 | 138/18723 | 6.06e-04 | 5.94e-03 | 29 |
GO:00351083 | Endometrium | AEH | limb morphogenesis | 29/2100 | 138/18723 | 6.06e-04 | 5.94e-03 | 29 |
GO:00487366 | Endometrium | AEH | appendage development | 33/2100 | 172/18723 | 1.41e-03 | 1.18e-02 | 33 |
GO:00601736 | Endometrium | AEH | limb development | 33/2100 | 172/18723 | 1.41e-03 | 1.18e-02 | 33 |
GO:0061448 | Endometrium | AEH | connective tissue development | 44/2100 | 252/18723 | 1.92e-03 | 1.51e-02 | 44 |
GO:0030326 | Endometrium | AEH | embryonic limb morphogenesis | 23/2100 | 116/18723 | 4.58e-03 | 2.95e-02 | 23 |
GO:0035113 | Endometrium | AEH | embryonic appendage morphogenesis | 23/2100 | 116/18723 | 4.58e-03 | 2.95e-02 | 23 |
GO:003109914 | Endometrium | EEC | regeneration | 45/2168 | 198/18723 | 6.19e-06 | 1.49e-04 | 45 |
GO:001097513 | Endometrium | EEC | regulation of neuron projection development | 79/2168 | 445/18723 | 6.80e-05 | 1.01e-03 | 79 |
GO:003510711 | Endometrium | EEC | appendage morphogenesis | 29/2168 | 138/18723 | 1.01e-03 | 8.89e-03 | 29 |
GO:003510811 | Endometrium | EEC | limb morphogenesis | 29/2168 | 138/18723 | 1.01e-03 | 8.89e-03 | 29 |
GO:004873611 | Endometrium | EEC | appendage development | 33/2168 | 172/18723 | 2.38e-03 | 1.75e-02 | 33 |
GO:006017311 | Endometrium | EEC | limb development | 33/2168 | 172/18723 | 2.38e-03 | 1.75e-02 | 33 |
GO:0031102 | Endometrium | EEC | neuron projection regeneration | 15/2168 | 60/18723 | 2.88e-03 | 2.03e-02 | 15 |
GO:00614481 | Endometrium | EEC | connective tissue development | 44/2168 | 252/18723 | 3.51e-03 | 2.36e-02 | 44 |
GO:00303261 | Endometrium | EEC | embryonic limb morphogenesis | 23/2168 | 116/18723 | 6.73e-03 | 3.93e-02 | 23 |
GO:00351131 | Endometrium | EEC | embryonic appendage morphogenesis | 23/2168 | 116/18723 | 6.73e-03 | 3.93e-02 | 23 |
GO:009872714 | Esophagus | ESCC | maintenance of cell number | 90/8552 | 134/18723 | 3.94e-07 | 5.43e-06 | 90 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRRX1 | SNV | Missense_Mutation | | c.587N>T | p.Ala196Val | p.A196V | P54821 | protein_coding | tolerated(0.06) | benign(0.142) | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRRX1 | SNV | Missense_Mutation | | c.96G>T | p.Lys32Asn | p.K32N | P54821 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRRX1 | SNV | Missense_Mutation | | c.284N>A | p.Arg95Gln | p.R95Q | P54821 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-BH-A18F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
PRRX1 | SNV | Missense_Mutation | | c.526G>C | p.Glu176Gln | p.E176Q | P54821 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PRRX1 | SNV | Missense_Mutation | novel | c.434N>A | p.Arg145Gln | p.R145Q | P54821 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-E2-A154-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PRRX1 | SNV | Missense_Mutation | rs761253714 | c.484N>A | p.Ala162Thr | p.A162T | P54821 | protein_coding | tolerated(0.07) | benign(0.236) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PRRX1 | SNV | Missense_Mutation | | c.587C>T | p.Ala196Val | p.A196V | P54821 | protein_coding | tolerated(0.06) | benign(0.142) | TCGA-E9-A1RE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
PRRX1 | SNV | Missense_Mutation | | c.257N>T | p.Ser86Leu | p.S86L | P54821 | protein_coding | tolerated(0.08) | benign(0.011) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
PRRX1 | SNV | Missense_Mutation | novel | c.434N>A | p.Arg145Gln | p.R145Q | P54821 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRRX1 | SNV | Missense_Mutation | novel | c.445T>C | p.Phe149Leu | p.F149L | P54821 | protein_coding | deleterious(0) | possibly_damaging(0.757) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |